Introduction {#Sec1}
============

Cisplatin (CPL) an anticancer drug is one of the most widely used in managing cancer such as head, neck, ovarian and lung cancer (Sahu et al. [@CR30]). However, CPL as a chemotherapeutic agent has limitations due to its side effects on normal tissues. CPL is excreted primarily via kidney and also is reported gets preferentially accumulated in renal tubules of patients undergoing chemotherapy which leads to nephrotoxicity causing acute kidney injury (Maimaitiyiming et al. [@CR18]). Despite advancements in strategies for countering CPL induced nephrotoxicity clinically still approximately 30% patients still face renal disfunction post receiving therapy of CPL (Khan et al. [@CR14]). Hence a huge hurdle lies ahead for finding a potential therapy which would prevent CPL induced nephrotoxicity during chemotherapy.

Reports have come up and have suggested various mechanisms involved in CPL induced renal damage which include, generation of reactive oxygen species (ROS), DNA damage, apoptosis and mitochondrial dysfunction (Nozaki et al. [@CR20]; Pan et al. [@CR22]). Report also has come up and has confirmed involvement of ERK pathway in development and progression of kidney damage (Guerrero-Beltrán et al. [@CR6]). Inflammation has been confirmed to be involved in pathogenesis of CPL induced renal damage (Rajasundari et al. [@CR26]). In addition to this nuclear related factor 2 (Nrf2) is reported to regulate physiological processes responsible for CPL induced renal damage (Shelton et al. [@CR31]), hence Nrf2 is regarded as vital target in countering CPL induced renal damage.

Flavonoids are phenolic compounds which are currently under major attention in the field of drug-discovery. Kaempferol is a naturally occurring flavonoid which occurs in number of plants (Yoshida et al. [@CR35]). Kaempferol exerts number of pharmacological properties such as reducing oxidative stress, anticancer and anti-inflammatory (Kampkotter et al. [@CR11]; Park et al. [@CR24]; Nguyen et al. [@CR19]). Kaempferol has been reported to show inhibitory action on PI3K/Akt pathway and cyclooxygenase-2 (Li et al. [@CR16]; Kang et al. [@CR13]). In a report recently Kaempferol was found to inhibit the activation of NF-κB (Kadioglu et al. [@CR10]). Kaempferol has been reported to exert activities such as myocardial ischemia protective effect (Zhou et al. [@CR38]), neuroprotective effect (Hussein et al. [@CR9]) antioxidant and hepatoprotective effect (Zang et al. [@CR37]). However, the effect of Kaempferol as a renoprotective agent in CPL induced kidney injury is missing. Therefore in the present investigation we examined the effects of Kaempferol on CPL mediated acute kidney injury and also study the mechanism involved.

Materials and methods {#Sec2}
=====================

Reagents and chemicals {#Sec3}
----------------------

Kaempferol (98% pure), CPL, Assay kit for measuring oxidative stress were procured from Sigma-Aldrich USA. Mouse specific ELISA kit for IL-12 and TNF-α were purchased from ThermoFisher USA. The NF-κB assay kit was bought from Abcam (USA).

Animals, groups and dosing {#Sec4}
--------------------------

For the present work we selected male Balb/C mice weighing 25--27 g aging 8 weeks. The animals were supplied by the pharmacology department of The first affiliated hospital of air force medical university Kidney internal medicine, Xi'an, Shaanxi, the approval number was AF0014AKI, China. The animals were housed under controlled conditions of temperature (23 ± 1 °C) and relative humidity (55 ± 5%) followed by 12 h dark/light cycle. The animals were provided to free access to standard chow diet and water ad libitum. All the animal protocols received approval from the Institutional animal ethical review board of The first affiliated hospital of air force medical university Kidney internal medicine, Xi'an, Shaanxi, China.

The animals were divided into five groups (6 animals per group), the groups received the treatments as follows. Group 1 (vehicle treated, control) 5% DMSO by intubation (p.o.) once a day for 14 consecutive days (2 weeks) and on the 12th day intraperitoneal injection of normal saline, Group 2 (Kaempferol treated) 200 mg/kg of body weight dissolved in DMSO by intubation (p.o.) once a day for 14 consecutive days (2 weeks) and on the 12th day intraperitoneal injection of normal saline, Group 3 (CPL treated) treated with 5% DMSO by intubation (p.o.) for 14 days a single dose of CPL in normal saline (20 mg/kg) via i.p route; Group 4 (CPL + Kaempferol-100) treated with Kaempferol 100 mg/kg body weight by p.o route for 14 days and injection of CPL on 12th day via i.p. Group 5 (CPL + Kaempferol-200) treated with Kaempferol 200 mg/kg by p.o route for 14 days and injection of CPL on 12th day via i.p. We selected the dose of Kaempferol and the duration of treatment referring previous study (Al-Numair et al. [@CR2]). Looking into the earlier reports we performed a pilot study with four doses of Kaempferol (50, 100, 150 and 200 mg/kg body weight) for assessing the effects of these doses on CPL mediated nephrotoxicity. The mice were given pre-treatment of Kaempferol for 12 days before injecting them with CPL on the 12th day the treatment of Kaempferol was continued for the remaining 2 days. After the completion of dosing the animals were evaluated for kidney function parameters i.e. creatinine and blood urea nitrogen. It was observed that Kaempferol at doses 100, 150 and 200 mg/kg showed ameliorating effect (p \< 0.01) on CPL mediated nephrotoxicity in mice. Hence for the study we selected dose of 100 and 200 mg/kg for our main study. At the end of dosing protocol the body weight of mice were evaluated, the blood was withdrawn following standard procedure by retro-orbital plexus, the serum was separated by centrifugation (10,000 rpm, 10 min) and were stored in cold. After this the mice were euthanized by CO~2~ asphyxiation method and the kidneys were isolated and were deep freezed in liquid nitrogen and then stored maintain − 80 °C till further analysis.

Evaluation of renal function {#Sec5}
----------------------------

The blood samples were centrifuged at 10,000 rpm for 10 min and serum was separated by centrifugation followed by estimation of creatinine and blood urea nitrogen using a auto-analyzer with the help of diagnostic kits (Creatinine Assay Kit, SigmaAldrich USA), in addition to this the kidney after isolation were weighed and weight compared to total body weight was determined.

Histopathology {#Sec6}
--------------

The isolated renal tissues were subjected for fixation using formalin (10%) for 48 h and then in paraffin wax. The tissues were processed to obtain section of 5 µm using rotary microtome (Leica Biosystems), the sections were deparaffinized using xylene and subjected to rehydration using alcohol. The sections were submitted to H & E staining for histological study using a light microscope (Olympus, Olympus BX Series).

Evaluation of oxidative stress in the renal tissues {#Sec7}
---------------------------------------------------

The kidney tissues were homogenized in a tissue homogenizer using phosphate buffer saline, the homogenates were centrifuged at 10,000 rpm for 10 min and the supernatants were analyzed for antioxidant enzyme activity of glutathione reductase (GR), glutathione S-transferase (GST), Superoxide dismutase (SOD) and Catalase (CAT), levels of glutathione (GSH) as per procedure described earlier (Ellman [@CR5]; Omaye et al. [@CR21]; Habig et al. [@CR7]; Carlberg and Mannervik [@CR4]). The levels of TBARS i.e. Thiobarbituric acid reactive substance, were also studied as described earlier (Sahu et al. [@CR28]). The protein content was determined by protein estimation kit (Sigma Aldrich USA).

Determination of myeloperoxidase (MPO) activity, levels of IL-18, TNF-α in kidney tissues {#Sec8}
-----------------------------------------------------------------------------------------

The kidney tissues were homogenated as descried earlier and the supernatants were evaluated for MPO activity as described earlier (Pulli et al. [@CR25]). The expression levels of IL-18 and TNF-α in kidney tissues were determined in the supernatants of tissue homogenates. The determination was done by commercially available kits (BD Bioscience, USA) following the supplied instructions.

Preparation of total, cytoplasmic protein and nuclear extracts from kidney tissues {#Sec9}
----------------------------------------------------------------------------------

For isolation of total, cytoplasmic and nuclear fraction from the isolated kidney tissues, we used RIPA lysis buffer, cytoplasmic extraction kit and NE-PER nuclear following the supplied instructions. The total protein content was done by protein estimation kit (Sigma Aldrich USA).

Immunoblot analysis {#Sec10}
-------------------

The total protein extracts were submitted for expression of Bcl-2 (1:1000), cleaved caspase-3 and -9 (1:1000), Bax (1:1000), cleaved PARP (1:1000), iNOS (1:500), p53 (1:1000), Nrf2 (1:500), ERK1/2 (1:1000), p-ERK1/2 (1:1000), JNK (1:1000), p-JNK (1:1000), HO-1 (1:1000), p38 (1:1000) were bought from Cell signaling Tech. USA and were estimated. The bands were viewed on Invitrogen iBright Imaging Systems (ThermoFisher USA).

NF-κB-DNA binding activity {#Sec11}
--------------------------

The assessing the NF-κB-DNA binding activity, nuclear fractions were isolated from mice. The activity was evaluated using ELISA kit (ThermoFisher USA) as per provided instructions.

Statistical analysis {#Sec12}
--------------------

All the statistical analysis was done using GraphPad Prism (version 5). All the data is produced as mean ± SEM, groups were correlated by one-way ANOVA. The value of P \< 0.05 was regarded as significant.

Results {#Sec13}
=======

Kaempferol ameliorates Cisplatin-mediated renal injury {#Sec14}
------------------------------------------------------

The outcomes of the experiment suggested that CPL alone treatment in mice resulted in impairment of renal activity 72 h post CPL injection (Fig. [1](#Fig1){ref-type="fig"}). The alone treatment of CPL caused significant increase in levels of creatinine and blood urea nitrogen in addition to this the weight of kidneys relative to control were found to increase significantly, whereas the body weight decreased significantly compared to vehicle treated mice (Fig. [1](#Fig1){ref-type="fig"}a--d). It was observed that the pretreatment of Kaempferol at both the selected doses i.e. at 100 and 200 mg/kg followed by exposure to CPL produced a attenuating effect on levels of blood urea nitrogen along with creatinine, the treatment also inhibited the loss in body weight and the increased relative weight of kidneys compared to mice exposed to only CPL therapy.Fig. 1Kaempferol attenuates renal injury markers and improves body weight. **a** Percentage change in body weight and **b** relative weight of kidneys. Treatment of Kaempferol improves the % body weight and relative weight of kidneys significantly compared to CPL alone treated group of mice. **c** Serum Creatinine and **d** blood urea nitrogen. Pre-treatment of Kaempferol improved the serum creatinine as well as blood urea nitrogen levels compared to CPL alone treated mice. The results are mean ± SEM. ^@^p \< 0.001 compared to vehicle treated control, \*\*p \< 0.01 and \*\*\*p \< 0.001 compared to CPL alone treated mice

The results of histological analysis (H & E staining) were in agreement to the results of functional analysis, the H & E stained kidney tissue sections of Kaempferol or vehicle treated showed normal kidney structure (Fig. [2](#Fig2){ref-type="fig"}a, b), whereas the mice exposed to CPL alone showed signs of structural damage in the form of necrosis, degeneration of tubules and infiltration of cells (Fig. [2](#Fig2){ref-type="fig"}c). In mice receiving pre-treatment of Kaempferol (100 mg/kg) followed by treatment of CPL demonstrated decreased in damage of tissue with presence of infrequent casts against the group treated with CPL alone (Fig. [2](#Fig2){ref-type="fig"}d). However, the mice which were pre-treated with Kaempferol at 200 mg/kg dose after treatment of CPL improved the changes in histopathology with decreased signs of formation of casts and infiltration of inflammatory cells in the renal tissues (Fig. [2](#Fig2){ref-type="fig"}e).Fig. 2Images of light microscope examination histopathology (H & E staining) of renal tissues. **a**, **b** Kidney tissue sections from vehicle treated control and mice treated with Kaempferol showing normal physiology. **c** The tissue sections of mice injected with CPL alone showing signs of damage such as infiltration of inflammatory cells, necrosis and presence vacuoles in epithelial, degeneration and development of hyaline casts. **d** Tissues sections of mice pretreated with Kaempferol (100 mg/kg) followed by injection of CPL. The tissue showed moderate to mild degenerative changes with few casts. **e** Tissues section of mice pretreated with Kaempferol (200 mg/kg) followed by injection of CPL. The tissue showed presence of normal tubular as well as glomerular structure with mild degenerative alterations, no presence of inflammatory cells was observed

Kaempferol ameliorates the CPL-mediated decrease in antioxidant defense of renal system {#Sec15}
---------------------------------------------------------------------------------------

The study of oxidative stress markers suggested that, treatment of CPL resulted in a significant suppression of the antioxidant defense of renal system (Table [1](#Tab1){ref-type="table"}). It was noticed that the levels of GSH decreased significantly (p \< 001), whereas the activity of antioxidant enzymes such as SOD, GST, CAT, NQO1 and Glutathione reductase (GR) were also significantly suppressed compared to vehicle treated mice. In the mice receiving pre-treatment of Kaempferol at a dose of 200 mg/kg reversed these altered oxidative stress parameters near to normal compared to mice treated with CPL alone. With the dose of 100 mg/kg Kaempferol caused a significant attenuation in the decrease in levels or activities of Glutathione reductase, SOD and GST, whereas the levels of CAT, GSH and NQO1 remained unaffected compared to mice treated with CPL alone.Table 1Antioxidant status in renal tissues in Cisplatin and Kaempferol treated miceMarkers of oxidative stressVehicle treated controlKaempferol (200 mg/kg)Cisplatin (20 mg/kg)Kaempferol (100 mg/kg) + CisplatinKaempferol (200 mg/kg) + CisplatinGSH levels0.15 ± 0.010.17 ± 0.010.089 ± 0.01^@^0.117 ± 0.010.159 ± 0.02\*\*SOD activity98.87 ± 1.44102.88 ± 1.8772.13 ± 1.35^\#^82.55 ± 1.77\*\*84.66 ± 1.02\*\*CAT activity12.44 ± 0.5512.13 ± 0.639.11 ± 0.44^\#^9.82 ± 0.2211.45 ± 0.55\*\*GR activity2.011 ± 0.352.39 ± 0.120.651 ± 0.12^\#^1.811 ± 0.35\*\*1.997 ± 0.25\*\*\*GST activity18.154 ± 1.2219.855 ± 1.2111.144 ± 0.77^@^15.994 ± 0.74\*24.112 ± 1.74\*\*\*NQO156.224 ± 4.1169.221 ± 1.9823.11 ± 0.44^\#^39.445 ± 3.1447.11 ± 2.88\*All the data are presented as mean ± S.E.M (n = 6). GSH mg/g tissue (reduced glutathione), SOD % of control (superoxide dismutase), CAT (U/mg of protein) Catalase, GR activity (Glutathione reductase) (U/mg protein), GST (glutathione S-transferase) nmol/min/mg/protein) and NQO1 (NAD quinone oxidoreductase 1) nmol of DCIP reduced/min/mg/protein^@^p \< 0.01 compared to control, ^\#^p \< 0.001 compared to control, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 compared to control

Kaempferol increases the Nrf2 nuclear translocation and expression of HO-1 in renal tissues {#Sec16}
-------------------------------------------------------------------------------------------

To find the involvement of Kaempferol in the activation of Nrf2, we evaluated the NRF2 nuclear translocation by studying the protein expression from the total protein fraction, cytoplasmic and nuclear fractions of renal tissues (Fig. [3](#Fig3){ref-type="fig"}). It was evidenced that, Nrf2 protein was significantly accumulated in renal tissues of CPL exclusively treated mice against the control mice. In the Kaempferol (200 mg/kg) pre-treated mice a significant increase in nuclear accumulation of Nrf2 was observed against the mice receiving CPL alone (Fig. [3](#Fig3){ref-type="fig"}a). Further it was observed that the levels of both HO-1 and Nrf2 (Fig. [3](#Fig3){ref-type="fig"}b, c) in the total protein extracts of renal tissues of mice receiving pre-treatment of Kaempferol (200 mg/kg) and then received injection of CPL were significantly elevated compared to mice receiving CPL alone. However no significant difference in levels of HO-1 and Nrf2 was observed in the total protein extracts in the vehicle treated and CPL alone treated mice.Fig. 3Kaempferol improved the expression levels of HO-1 and nuclear translocation Nrf2 in renal tissues of CPL treated mice. Western blot analysis demonstrating **a** Nuclear and Cytoplasmic translocation of Nrf2. For studying Nuclear translocation Lamin-B was selected a loading control whereas for cytoplasmic translocation actin was control. **b** Showing protein levels of Nrf2, actin was selected as loading control. **c** Expression levels of HO-1 in kidney tissues. **d** Quantitative results of densitometric analysis for ratio of Nuclear Nrf2 and cytoplasmic Nrf2. **e** Quantitative results of levels of Nrf2 relative to actin. **f** Quantitative results of levels of heme oxygenase-1 relative to actin. The results are mean ± SEM. ^\#^p \< 0.05 compared to control mice, \*p \< 0.05 and \*\*p \< 0.01 compared to cisplatin alone treated mice

Kaempferol attenuates Cisplatin mediated lipid peroxidation and levels of inducible NO synthase in renal tissues {#Sec17}
----------------------------------------------------------------------------------------------------------------

The results demonstrated that the renal tissues of mice injected with CPL alone had significantly increased levels of inducible nitric oxide synthase (iNOS) and thiobarbituric acid reactive substances (TBARS) (Fig. [4](#Fig4){ref-type="fig"}a--c) which is marker for lipid per-oxidation compared to vehicle treated mice. The pre-treatment of Kaempferol significantly decreased the levels of TBARS at both the concentrations (100 and 200 mg/kg) and also modulated the expression levels of iNOS compared to mice receiving injection of CPL alone.Fig. 4Kaempferol decreased the cisplatin mediated lipid peroxidation and levels of iNOS. **a** Marker of lipid peroxidation i.e. Thiobarbituric acid reactive substances (TBARS), the levels were increased in renal tissues of cisplatin alone treated mice. Treatment of Kaempferol decreased the levels of TBARS in cisplatin injected mice at both the doses. **b** Showing quantitative results of expression of iNOS whereas **c** Shows the western blots for expression of iNOS. Treatment of Kaempferol decreased the levels of iNOS at both the doses in mice treated with Cisplatin. The results are mean ± SEM. ^\#^p \< 0.001 compared to control, ^@^p \< 0.01 compared to control group, \*p \< 0.05, \*\*\*p \< 0.001 compared to cisplatin alone treated group

Kaempferol modulates the expression of Cisplatin mediated apoptotic-related protein {#Sec18}
-----------------------------------------------------------------------------------

The expression of apoptosis related proteins suggested that the levels of major proteins such as caspase-9/-3, Bax/Bcl-2 ratio, TP53 and PARP were upregulated in the renal tissue homogenates of mice injected with CPL alone compared to vehicle treated mice (Fig. [5](#Fig5){ref-type="fig"}). It was observed that the pretreatment of Kaempferol inhibited the up-regulation of CPL mediated TP53 and Bax/Bcl-2 ratio and also improved the levels of PARP and levels of Bax/Bcl-2 ratio in renal tissue homogenates compared to CPL alone treated mice.Fig. 5Kaempferol ameliorates cisplatin mediated apoptosis proteins in kidney tissue of mice. **a** Western blot analysis showing the expression of cleaved caspase-3, cleaved caspase-9, Bax, Bcl-2, TP53 and cleaved PARP, Actin was selected as loading control. **b** Quantitative results of Bax/Bcl-2 ratio. **c** Quantitative results of TP53 and **d** Quantitative results of Cleaved PARP, caspase-3 and caspase-9. The results are mean ± SEM. ^@^p \< 0.05 and ^\#^p \< 0.01 compared to vehicle treated control, \*p \< 0.05 and \*\*\*p \< 0.001 compared to cisplatin alone treated group

Kaempferol blocks Cisplatin-mediated degradation of IκBα and nuclear translocation of NF-κB and its DNA binding {#Sec19}
---------------------------------------------------------------------------------------------------------------

The outcomes suggested a significant rise in the accumulation of NF-κB in the nuclear fraction of renal tissues of mice treated with CPL compared to vehicle treated mice (Fig. [6](#Fig6){ref-type="fig"}a). Also there was significant increase in levels of pIKKα/β with degradation of p-IκBα in the cytoplasmic fractions of renal tissues in CPL exclusive treated mice compared to the vehicle treated group (Fig. [6](#Fig6){ref-type="fig"}b). The results also suggested increase in DNA binding of NF-κB in the nuclear fractions of mice injected with CPL alone (Fig. [6](#Fig6){ref-type="fig"}c). It was observed that pre-treatment of Kaempferol at the dose of 200 mg/kg forbade the CPL mediated phosphorylation of IKKα/β and IκBα, prevented the degradation of DNA binding potential of NF-κB against the mice treated with CPL alone (Fig. [6](#Fig6){ref-type="fig"}d).Fig. 6Kaempferol inhibits the expression of CPL mediated NF-κB proteins. **a**, **b** Western blot analysis demonstrating expression of nuclear translocation of NF-κB proteins, phosphorylated-IκBα, phosphorylated-IKKα/β and IκBα in isolated renal tissues. **c** Quantitative analysis for DNA binding activity of NF-κB by measuring optical density at 450 nm. **d** Relative expression levels for ratio of nuclear NF-κB/cytoplasmic NF-κB, phosphorylated-IKKα and ratio of phosphorylated-IKKα/β ratio. The results are mean ± SEM. ^\#^p \< 0.05 and ^@^p \< 0.001 compared to vehicle treated control group, \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 compared CPL alone treated group

Kaempferol modulates Cisplatin-mediated inflammation in renal tissues {#Sec20}
---------------------------------------------------------------------

For evaluating the extent of inflammation and expression levels of IL-12 and TNF-α which are the pro-inflammatory cytokines and myeloperoxidase (MPO) activity was evaluated. It was observed that the levels of IL-12 and TNF-α along with activity of MPO (Fig. [7](#Fig7){ref-type="fig"}a--c) were significantly high in CPL alone treated mice against the vehicle treated group. Pre-treatment of Kaempferol 100 and 200 mg/kg was found exert modulating effect in mice treated with CPL compared to alone treated group.Fig. 7Pre-treatment of Kaempferol attenuates levels of inflammatory mediators in CPL mediated renal injury. **a** Quantitative results of expression of IL-12. **b** Quantitative results of TNF-α and **c** Results of MPO activity in renal tissues. The results are mean ± SEM. ^@^p \< 0.01 and ^\#^p \< 0.001 compared to control group mice, \*p \< 0.05 and \*\*\*p \< 0.001 compared to CPL alone treated mice

Kaempferol blocks the MAPK cascade {#Sec21}
----------------------------------

Western blot analysis was done to evaluate the effect of CPL and Kaempferol treatment on the activation of MAPK pathway. The results suggested (Fig. [8](#Fig8){ref-type="fig"}) that levels of JNK, ERK1/2 and p38 were upregulated in the renal tissues of mice injected with CPL alone compared to vehicle treated mice. Pre-treatment of Kaempferol significantly attenuated the expression of JNK, p38 and ERK1/2 compared to mice treated with CPL alone.Fig. 8Pre-treatment of Kaempferol attenuated the expression levels of p38, phosphorylated-JNK, JNK, phosphorylated-p38, p38, phosphorylated-ERK1/2 and ERK1/2 in renal tissues of mice. **a** Western blots of p38, phosphorylated-JNK, JNK, phosphorylated-p38, p38, phosphorylated-ERK1/2 and ERK1/2. **b** Quantitative results of expression of phosphorylated-JNK and JNK. **c** Quantitative results of expression of phosphorylated-p38 and p38. **d** Quantitative results of expression of phosphorylated-ERK1/2 and ERK1/2 in renal tissues. The results are mean ± SEM. ^\#^p \< 0.01 compared to control vehicle treated mice, \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 compared to CPL alone treated mice

Discussion {#Sec22}
==========

Cisplatin induced nephrotoxicity leading to acute renal injury is dangerous complication specially in subjects involved in chemotherapy (Sahu et al. [@CR29]; Kang et al. [@CR12]). Here in the present work we demonstrated that Kaempferol a plant-derived flavonoid compound ameliorates the CPL mediated nephrotoxicity in mice. We evidenced that pre-treatment of Kaempferol decreased oxidative stress, inflammation and apoptosis in kidney tissues of mice subjected to CPL induced nephrotoxicity. The results affirmed renoprotective effect of Kaempferol against CPL induced renal injury. Previously it has been reported that deposition of CPL in renal tubules lead to increased production of reactive oxygen species which attacks endogenous targets like DNA (Kang et al. [@CR12]; Zirak et al. [@CR40]). In addition to this CPL mediated ROS triggers signaling cascades such as p53, MAPK and NF-κB to further worsen its damaging effects (Sung et al. [@CR32]). In CPL induced nephrotoxicity iNOS has been identified to play important role (Zirak et al. [@CR40]). Kaempferol a flavonoid has been reported to show potent antioxidant effect (Al-Numair et al. [@CR2]). Kaempferol decreases the generation of free radicals and reactive oxygen species, it is also reported to induce scavenging effect on superoxide anion, hydroxyl radical and peroxynitrile (Wang et al. [@CR33]; Heijnen et al. [@CR8]). Kaempferol also enhances the activity of antioxidant enzymes such as catalase, superoxide dismutase and heme oxygenase-1 (Klaunig and Kamendulis [@CR15]). In the present study CPL caused a significant decrease in activities of antioxidant enzymes and also impaired the antioxidant defense mechanism in the renal tissues. In addition to this CPL also increased the levels of nitrites, iNOS and TBARS which is marker for lipid per-oxidation in mice. We evidenced that pre-treatment with Kaempferol attenuated these changes in the CPL treated mice. Therefore these results suggest that attenuation of CPL mediated nephrotoxicity by Kaempferol partly may be due to its activity to reduce oxidative stress and levels of nitrile ions.

Nrf2 is a protein which is responsible for regulating the expression levels of antioxidant proteins which protect against oxidative damage due to injury and inflammation. Studies earlier have investigated the involvement of Nrf2 particularly in strategies for upregulation of Nrf2 in preventing CPL mediated nephrotoxicity (Park et al. [@CR23]; Aleksunes et al. [@CR1]). To evaluate the involvement of Kaempferol pre-treatment on levels of Nrf2 in renal tissues and its role in CPL mediated nephrotoxicity, the Nrf2 nuclear translocation and levels of Heme oxygenase-1 (HO-1) by immunoblotting study. It was observed that treatment of CPL resulted in significant upregulation of Nrf2 in the renal tissues compared to vehicle treated mice. However Kaempferol pre-treated mice showed significant increase in the nuclear accumulation of Nrf2 against the CPL alone treated animals. These findings are in agreement to the role of Kaempferol in reducing oxidative stress via GSK3β-Nrf2 pathway (Hussein et al. [@CR9]). HO-1 is identified to be an Nrf2 regulated gene involved in balancing oxidative stress (Sahin et al. [@CR27]). The outcomes showed that the levels of HO-1 in Kaempferol pre-treated mice receiving treatment of CPL were significantly increased compared to CPL alone injected group of mice. The results hence suggest that over-expression of Nrf2 and its regulated protein HO-1 mediated by Kaempferol pretreatment is partly due to its discussed antioxidant defense mechanisms in renal tissues.

Cisplatin mediated nephrotoxicity involves number of pathways (Kang et al. [@CR12]). TP53 is pro-apoptotic protein and it is associated with pathway involved with CPL mediated nephrotoxicity (Sung et al. [@CR32]; Wei et al. [@CR34]). In addition to this, a earlier study TP53 knockout mice showed resistance to CPL induced renal injury (Wei et al. [@CR34]). Also, it has been evidenced that induction of TP53 can lead to apoptosis via activating the pro-apoptotic protein Bax (Kang et al. [@CR12]). Here in the current work, we demonstrated that Kaempferol pre-treatment blocked the CPL induced TP53 levels in renal tissues. We hence confirm that Kaempferol suppresses the CPL mediated cell death by regulating TP53 in renal tissues.

Inflammation is a crucial mechanism in development of CPL mediated kidney injury (Pulli et al. [@CR25]). CPL causes release of IL-12, TNF-α and IL-1β which are the pro-inflammatory cytokines and also leads to infiltration of leukocytes within 72 h of kidney damage (Guerrero-Beltrán et al. [@CR6]). A study earlier suggested that inhibition of TNF-α decreases CPL mediated infiltration of leucocytes and hence ameliorates kidney injury (Sahu et al. [@CR29]). Here we showed that the pre-treatment of Kaempferol caused a significant decrease in CPL mediated MPO activity.

NF-κB i.e. Nuclear factor-kappa B is present in the cytoplasm along with IκBα which is a inhibitory protein, it has been evidenced that phosphorylation of IκBα is involved in activation of NF-κB which translocates it to the nucleus where it triggers genes associated with inflammation. A report concluded that NF-κB is involved in CPL mediated nephrotoxicity (Yu et al. [@CR36]). Here it was observed that, Kaempferol pre-treatment decreased the release of pro-inflammatory cytokines (IL-12 and TNF-α) and also modulated the levels of NF-κB by inhibiting the phosphorylation of IKK and degradation of IκBα and hence ameliorated the CPL mediated inflammation.

The MAPKs groups of proteins comprise p38, c-Jun N-terminal kinases (JNK) and extracellular-receptor kinases (ERK1/2) proteins. Previously a study has confirmed involvement of MAPK cascade in CPL mediated renal inflammation and cell death (Basu and Krishnamurthy [@CR3]). Also, a study suggested treatment of CPL is responsible for activation of ERK1/2 causing apoptosis in renal cells through TP53 and Bax pathway (Liu et al. [@CR17]; Zhuang and Schnellmann [@CR39]). Here we observed a significant increase in levels of p38, pERK1/2 and JNK in renal tissues of CPL induced mice post 72 h of injecting CPL. Kaempferol pretreatment inhibited the activation of p38, ERK and JNK establishing a potential mechanism for ameliorating effect of Kaempferol.

In conclusion, the findings of the present research suggested and established that pre-treatment of Kaempferol in CPL therapy could prevent CPL mediated nephrotoxicity. The ameliorating effect of Kaempferol seems to due to decreasing oxidative stress, inflammation and apoptosis via inhibiting MAPK and NF-κB cascade and up-regulating Nrf-2/HO-1 levels.
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